Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients

Giovanni Scambia, Margherita Fossati, Andrea Fattorossi, Madi R. Madiyalakan, Yolanda D. Mahnke, Christopher Nicodemus

Risultato della ricerca: Contributo in rivistaArticolo in rivista

8 Citazioni (Scopus)

Abstract

The standard-of-care (SOC) first-line therapy for ovarian cancer (OC) patients is plagued with high relapse rates. Several studies indicated the immune system’s prominent role changing the disease course in OC patients. Chemo-immunotherapy regimens, currently being explored, include oregovomab, which is a monoclonal antibody specific for the OC associated antigen carbohydrate/cancer antigen 125 (CA125) that yielded promising results when administered together with SOC in a previous study. The QPT-ORE-002 multi-site phase II randomized study demonstrated that in patients with advanced OC, oregovomab combined with first-line SOC improved overall and progression-free survival, compared to SOC alone. The study included an Italian cohort in which we demonstrated that adding oregovomab to SOC resulted in increased patient numbers with amplified CA125-specific CD8+T lymphocytes/ml peripheral blood counts, which might explain the improved therapeutic effect of SOC + oregovomab over SOC alone. Predictive for oregovomab efficacy was a less suppressive immune environment at baseline as indicated by low numbers of circulating myeloid-derived suppressor cells, subset type 4, and a low neutrophil-and-monocyte to lymphocyte ratio.
Lingua originaleEnglish
pagine (da-a)383-397
Numero di pagine15
RivistaCANCER IMMUNOLOGY, IMMUNOTHERAPY
Volume69
DOI
Stato di pubblicazionePubblicato - 2020

Keywords

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols
  • Carboplatin
  • Female
  • Humans
  • Immune response
  • Immunotherapy
  • Middle Aged
  • Oregovomab
  • Ovarian Neoplasms
  • Ovarian cancer
  • Paclitaxel
  • Personalized medicine
  • Precision Medicine
  • Predictive biomarkers

Fingerprint

Entra nei temi di ricerca di 'Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients'. Insieme formano una fingerprint unica.

Cita questo